These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 26925841)

  • 61. Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma.
    Healy JR; Hart LS; Shazad AL; Gagliardi ME; Tsang M; Elias J; Ruden J; Farrel A; Rokita JL; Li Y; Wyce A; Barbash O; Batra V; Samanta M; Maris JM; Schnepp RW
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28267. PubMed ID: 32307821
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study.
    Kim JW; Lee KH; Kim JW; Suh KJ; Nam AR; Bang JH; Bang YJ; Oh DY
    Br J Cancer; 2019 Aug; 121(4):332-339. PubMed ID: 31312030
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Blockade of the extracellular signal-regulated kinase pathway enhances the therapeutic efficacy of microtubule-destabilizing agents in human tumor xenograft models.
    Watanabe K; Tanimura S; Uchiyama A; Sakamoto T; Kawabata T; Ozaki K; Kohno M
    Clin Cancer Res; 2010 Feb; 16(4):1170-8. PubMed ID: 20145173
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Inhibition of MEK pathway in vestibular schwannoma cell culture.
    Neff BA; Voss SG; Schmitt WR; Driscoll CL; Link MJ; Beatty CW; Kita H
    Laryngoscope; 2012 Oct; 122(10):2269-78. PubMed ID: 22886786
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Immunohistochemical staining of phosphorylated-ERK in post-chemotherapeutic samples is a potential predictor of the prognosis of neuroblastoma.
    Tanaka T; Togashi Y; Takeuchi Y; Higashi M; Fumino S; Tajiri T
    Pediatr Surg Int; 2021 Feb; 37(2):287-291. PubMed ID: 33394087
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment.
    Kim BJ; Zheng ZY; Lei JT; Holt MV; Chen A; Peng J; Fandino D; Singh P; Kennedy H; Dou Y; Chica-Parrado MDR; Bikorimana E; Ye D; Wang Y; Hanker AB; Mohamed N; Hilsenbeck SG; Lim B; Asirvatham JR; Sreekumar A; Zhang B; Miles G; Anurag M; Ellis MJ; Chang EC
    Cancer Res Commun; 2023 Jul; 3(7):1366-1377. PubMed ID: 37501682
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines.
    Marampon F; Gravina GL; Popov VM; Scarsella L; Festuccia C; La Verghetta ME; Parente S; Cerasani M; Bruera G; Ficorella C; Ricevuto E; Tombolini V; Di Cesare E; Zani BM
    Int J Oncol; 2014 Jan; 44(1):285-94. PubMed ID: 24189697
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
    Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
    Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
    [TBL] [Abstract][Full Text] [Related]  

  • 69. MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.
    Ioannou M; Lalwani K; Ayanlaja AA; Chinnasamy V; Pratilas CA; Schreck KC
    Mol Cancer Ther; 2024 Sep; 23(9):1261-1272. PubMed ID: 38714355
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Metformin increases antitumor activity of MEK inhibitor binimetinib in 2D and 3D models of human metastatic melanoma cells.
    Ryabaya O; Prokofieva A; Akasov R; Khochenkov D; Emelyanova M; Burov S; Markvicheva E; Inshakov A; Stepanova E
    Biomed Pharmacother; 2019 Jan; 109():2548-2560. PubMed ID: 30551515
    [TBL] [Abstract][Full Text] [Related]  

  • 71.
    Pucciarelli D; Angus SP; Huang B; Zhang C; Nakaoka HJ; Krishnamurthi G; Bandyopadhyay S; Clapp DW; Shannon K; Johnson GL; Nakamura JL
    Mol Cancer Ther; 2020 Nov; 19(11):2382-2395. PubMed ID: 32847978
    [TBL] [Abstract][Full Text] [Related]  

  • 72. ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERK.
    Munck JM; Berdini V; Bevan L; Brothwood JL; Castro J; Courtin A; East C; Ferraldeschi R; Heightman TD; Hindley CJ; Kucia-Tran J; Lyons JF; Martins V; Muench S; Murray CW; Norton D; O'Reilly M; Reader M; Rees DC; Rich SJ; Richardson CJ; Shah AD; Stanczuk L; Thompson NT; Wilsher NE; Woolford AJ; Wallis NG
    Mol Cancer Ther; 2021 Oct; 20(10):1757-1768. PubMed ID: 34330842
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss.
    Beauchamp EM; Woods BA; Dulak AM; Tan L; Xu C; Gray NS; Bass AJ; Wong KK; Meyerson M; Hammerman PS
    Mol Cancer Ther; 2014 Feb; 13(2):475-82. PubMed ID: 24296828
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Protective effect of the dopamine D(3) receptor agonist (7-OH-PIPAT) against apoptosis in malignant peripheral nerve sheath tumor (MPNST) cells.
    Castorina A; Giunta S; D'Agata V
    Int J Oncol; 2010 Oct; 37(4):927-34. PubMed ID: 20811714
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evaluation of the RAS signaling network in response to MEK inhibition using organoids derived from a familial adenomatous polyposis patient.
    Osumi H; Muroi A; Sakahara M; Kawachi H; Okamoto T; Natsume Y; Yamanaka H; Takano H; Kusama D; Shinozaki E; Ooki A; Yamaguchi K; Ueno M; Takeuchi K; Noda T; Nagayama S; Koshikawa N; Yao R
    Sci Rep; 2020 Oct; 10(1):17455. PubMed ID: 33060766
    [TBL] [Abstract][Full Text] [Related]  

  • 76. V211D Mutation in MEK1 Causes Resistance to MEK Inhibitors in Colon Cancer.
    Gao Y; Maria A; Na N; da Cruz Paula A; Gorelick AN; Hechtman JF; Carson J; Lefkowitz RA; Weigelt B; Taylor BS; Zhao H; Reis-Filho JS; de Stanchina E; Rosen N; Yao Z; Yaeger R
    Cancer Discov; 2019 Sep; 9(9):1182-1191. PubMed ID: 31227518
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Induction of immunoglobulin transcription factor 2 and resistance to MEK inhibitor in melanoma cells.
    Hur EH; Goo BK; Moon J; Choi Y; Hwang JJ; Kim CS; Bae KS; Choi J; Cho SY; Yang SH; Seo J; Lee G; Lee JH
    Oncotarget; 2017 Jun; 8(25):41387-41400. PubMed ID: 28574827
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Synergy between loss of NF1 and overexpression of MYCN in neuroblastoma is mediated by the GAP-related domain.
    He S; Mansour MR; Zimmerman MW; Ki DH; Layden HM; Akahane K; Gjini E; de Groh ED; Perez-Atayde AR; Zhu S; Epstein JA; Look AT
    Elife; 2016 Apr; 5():. PubMed ID: 27130733
    [TBL] [Abstract][Full Text] [Related]  

  • 79. NF1 regulation of RAS/ERK signaling is required for appropriate granule neuron progenitor expansion and migration in cerebellar development.
    Sanchez-Ortiz E; Cho W; Nazarenko I; Mo W; Chen J; Parada LF
    Genes Dev; 2014 Nov; 28(21):2407-20. PubMed ID: 25367036
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma.
    Trousil S; Chen S; Mu C; Shaw FM; Yao Z; Ran Y; Shakuntala T; Merghoub T; Manstein D; Rosen N; Cantley LC; Zippin JH; Zheng B
    J Invest Dermatol; 2017 May; 137(5):1135-1143. PubMed ID: 28143781
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.